Acquipharma
4
9M
2
0.50
- Areas of investment
Summary
Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2018.
The usual cause for the fund is to invest in rounds with 2 partakers. Despite the Acquipharma, startups are often financed by Karmel Capital, CARB-X, Biotechnology Industry Research Assistance Council(BIRAC). The meaningful sponsors for the fund in investment in the same round are UTEC- University of Tokyo Edge Capital, 3one4 Capital.
The fund has no specific favorite in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical, Product Research. Among the most popular portfolio startups of the fund, we may highlight Burl Concepts, BUGWORKS Research, Inc.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Follow on index
- 0.50
- Investments by industry
- Life Science (3)
- Biotechnology (3)
- Pharmaceutical (3)
- Product Research (3)
- Health Care (3) Show 3 more
- Investments by region
-
- India (3)
- United States (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 0.75
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| BUGWORKS Research | 09 Feb 2022 | Biotechnology, Health Care, Life Science, Pharmaceutical, Product Research | Early Stage Venture | 18M | Karnataka, Bengaluru, India |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.